Semaglutide and Kidney Health: What the FLOW Trial Reveals
For years, the conversation around semaglutide focused on weight loss and blood sugar control. That made sense - those are the reasons most people start the medication. But a major clinical trial publ
In this article
For years, the conversation around semaglutide focused on weight loss and blood sugar control. That made sense - those are the reasons most people start the medication. But a major clinical trial published in 2024 shifted the discussion in a meaningful direction.
The FLOW trial showed that semaglutide dramatically reduced the progression of chronic kidney disease in patients with type 2 diabetes. It was the kind of result that made nephrologists pay attention to a medication they had previously considered a weight loss tool.
This article breaks down what the FLOW trial found, how semaglutide interacts with kidney function, and what the research means for people living with CKD or at risk for it.
*Compounded semaglutide is not FDA-approved. This article is for educational and informational purposes only. It is not medical advice. Consult your licensed healthcare provider before making any treatment decisions.*
---
What Is Chronic Kidney Disease?
Chronic kidney disease (CKD) is a condition in which the kidneys lose their ability to filter waste from the blood over time. It is measured by the estimated glomerular filtration rate (eGFR) and the presence of albumin in the urine. There are five stages of CKD, with Stage 5 representing kidney failure.
CKD affects approximately 15% of U.S. adults, and it is closely tied to two conditions that are increasingly common: type 2 diabetes and obesity. Diabetes is the leading cause of kidney failure in the United States. High blood sugar damages the small blood vessels in the kidneys over years, reducing their filtering capacity.
This is where the connection to GLP-1 medications becomes important.
---
How GLP-1 Receptor Agonists Protect the Kidneys
GLP-1 receptor agonists like semaglutide work primarily by mimicking the body's natural glucagon-like peptide-1, a hormone that regulates blood sugar, appetite, and insulin secretion. But GLP-1 receptors are not only in the gut and brain. They are present in kidney tissue as well.
Research has identified several mechanisms through which semaglutide and other GLP-1 receptor agonists may protect the kidneys:
Natriuresis. GLP-1 receptor activation in the kidneys promotes sodium excretion. This reduces fluid retention, lowers blood pressure, and decreases the mechanical strain on kidney filtration units (nephrons). Chronically elevated sodium reabsorption is a driver of kidney damage in diabetic nephropathy.
Anti-inflammatory effects. Persistent low-grade inflammation in kidney tissue accelerates CKD progression. GLP-1 receptor agonists reduce inflammatory signaling within the kidney, including markers like NF-kB pathways that contribute to nephron damage.
Reduced oxidative stress. Oxidative stress - damage from unstable oxygen molecules - is a major mechanism of kidney injury in metabolic disease. Semaglutide has been shown to reduce oxidative stress markers in kidney tissue, potentially slowing structural damage.
Anti-fibrotic pathways. As kidneys are damaged, they develop scar tissue (fibrosis) that replaces functional filtering cells. GLP-1 receptor agonists appear to attenuate fibrotic signaling in the kidney. This is meaningful because fibrosis is largely irreversible - slowing it down preserves more functioning kidney tissue for longer.
A 2026 review in *Current Cardiology Reports* (PMID: 41880122) confirmed that these nephroprotective mechanisms operate consistently across different body weight categories, distinguishing kidney protection from cardiovascular benefits that tend to be more pronounced at higher BMI.
These mechanisms help explain why the FLOW trial results were not entirely surprising to researchers who had been watching early-stage GLP-1 kidney data.
---
The FLOW Trial: What It Was and What It Found
Study Design
FLOW (semaglutide in patients with type 2 diabetes and chronic kidney disease) was a randomized, double-blind, placebo-controlled trial involving 3,533 participants across 28 countries. Participants had type 2 diabetes and CKD at stages 2 through 4, with elevated urine albumin indicating kidney stress.
Participants were randomized to receive either once-weekly subcutaneous semaglutide 1.0 mg or placebo. The median follow-up was approximately 3.4 years. Background kidney-protective medications (RAS inhibitors, SGLT2 inhibitors where indicated) were allowed, making this a real-world reflection of how semaglutide would be used alongside standard care.
Primary Results
The results were published in the *New England Journal of Medicine* in 2024 (PMID: 38785209).
The primary composite outcome was: sustained decrease in kidney function (40% or greater decline in eGFR), kidney failure, death from kidney disease, or death from cardiovascular causes.
Semaglutide reduced this composite primary endpoint by 24% compared to placebo. That means roughly one in four major kidney disease events was prevented over the trial period.
Breaking down the components:
- Sustained eGFR decline of 40% or more: Lower rate in the semaglutide group
- Kidney failure (dialysis or transplant): Significantly reduced
- Death from kidney disease: Lower in the semaglutide group
- Death from cardiovascular causes: Also lower, showing the two outcomes are intertwined
Secondary Findings
Beyond the primary endpoint, FLOW also found:
- A meaningful reduction in the rate of eGFR decline per year, indicating that semaglutide slowed the loss of kidney function
- An 18% reduction in major adverse cardiovascular events (the 3-point MACE composite of cardiovascular death, non-fatal heart attack, or non-fatal stroke; hazard ratio 0.82; 95% CI, 0.68 to 0.98; P=0.029) [(Perkovic et al., *N Engl J Med*, 2024; PMID 38785209)](https://pubmed.ncbi.nlm.nih.gov/38785209/)
- A reduction in blood pressure and body weight in the semaglutide group, contributing to the kidney-protective effect
---
What the Results Mean in Context
The FLOW trial matters because CKD treatment options have historically been limited. The major kidney-protective medications before FLOW were:
- ACE inhibitors and ARBs: Block the renin-angiotensin system, reducing protein in urine and slowing CKD progression. First-line therapy since the 1990s.
- SGLT2 inhibitors: Newer class (empagliflozin, dapagliflozin) that also reduce kidney disease progression via a different mechanism (glucosuria, pressure reduction in the glomerulus).
A prespecified sub-analysis of the FLOW trial published in *JACC* in 2024 also found that semaglutide reduced the composite of heart failure events and cardiovascular death by 27% in this CKD population (hazard ratio 0.73; 95% CI, 0.62 to 0.87; P=0.0005), a population known to be at very high cardiac risk [(Pratley et al., *J Am Coll Cardiol*, 2024; PMID 39217553)](https://pubmed.ncbi.nlm.nih.gov/39217553/).
This dual benefit (kidney and cardiovascular protection) is consistent with what was seen in the SELECT trial (PMID: 37952131), which enrolled 17,604 patients with obesity and cardiovascular disease but no diabetes. SELECT showed semaglutide reduced major cardiovascular events by 20% over 3.3 years, suggesting the drug's cardiovascular effects are robust across different patient populations.
---
Who This Matters Most For
The FLOW trial enrolled patients who already had established CKD (stages 2-4) and type 2 diabetes. If you fall into this group, the trial's findings are directly relevant to your care.
But there are other situations where kidney health and GLP-1 medications intersect:
Patients with early metabolic disease. CKD often develops silently. People with obesity, pre-diabetes, or type 2 diabetes frequently have subclinical kidney damage detectable only through urine albumin testing. GLP-1-related kidney protection may matter most early, before structural damage becomes severe.
Patients who have been prescribed semaglutide for weight loss. If you are using semaglutide and also have a family history of kidney disease or have been told your eGFR is trending down, the FLOW findings are relevant. Talk to your provider about whether kidney monitoring should be part of your follow-up plan.
Patients considering dosing decisions. The FLOW trial used 1.0 mg weekly, the dose approved for type 2 diabetes (Ozempic), not the 2.4 mg weekly dose approved for weight management (Wegovy). The kidney-protective mechanisms appear dose-related in animal models, but human dose-response data is still developing.
---
Practical Takeaways
The FLOW trial does not change what you should do without a provider's guidance. But it does change the conversation in a few useful ways:
Kidney function should be monitored. Creatinine, eGFR, and urine albumin-to-creatinine ratio (uACR) are simple blood and urine tests. If you are on semaglutide and have any CKD risk factors - diabetes, hypertension, family history, or a history of kidney stones - ask your provider to include these in your routine labs.
Semaglutide's benefits extend beyond the scale. For patients who focus exclusively on weight loss as the outcome, the FLOW data is a reminder that GLP-1 medications may be doing more behind the scenes. This can be meaningful when discussing whether to continue treatment even in a weight loss plateau.
The combination with SGLT2 inhibitors is worth discussing. Approximately half of FLOW participants were on SGLT2 inhibitors as background therapy. The benefit of semaglutide appeared on top of that protection. If you have CKD and type 2 diabetes, your provider may consider both classes together.
---
Frequently Asked Questions
Does semaglutide protect kidney function in people without diabetes? The FLOW trial enrolled people with type 2 diabetes, so the direct evidence applies to that group. Research on non-diabetic CKD and semaglutide is ongoing, but the SELECT trial - which enrolled non-diabetic patients - showed cardiovascular benefits, suggesting the drug's effects on metabolic stress extend beyond glucose control.
Can semaglutide cause kidney problems? Rare cases of acute kidney injury have been reported with GLP-1 medications, generally linked to severe nausea, vomiting, and dehydration in the early weeks of treatment. Staying hydrated and managing gastrointestinal side effects reduces this risk. The long-term kidney data from FLOW actually points in the opposite direction - toward net kidney protection over time.
Is compounded semaglutide the same as what was used in FLOW? No. The FLOW trial used Novo Nordisk's branded injectable semaglutide (Ozempic). Compounded semaglutide is a separate preparation made by licensed compounding pharmacies. It is not FDA-approved and has not been evaluated in kidney outcomes trials. Clinical decisions about compounded semaglutide should involve a licensed healthcare provider.
Does semaglutide reduce protein in the urine? Yes. The FLOW trial and prior smaller studies showed reductions in urine albumin-to-creatinine ratio in patients on semaglutide. Proteinuria (protein in urine) is a marker of kidney damage, so reducing it is clinically meaningful.
---
Summary
The FLOW trial added a significant chapter to what we know about semaglutide. A 24% reduction in major kidney disease events is a meaningful outcome in a population that has historically had limited options for slowing CKD progression.
For patients managing type 2 diabetes, obesity, or both, the emerging picture is one of overlapping benefits - weight, blood sugar, cardiovascular risk, and now kidney function - rather than a single-purpose medication. That picture will continue to develop as longer follow-up data and broader trials accumulate.
If you have questions about your kidney health and how GLP-1 medications might factor into your care plan, the most direct path is a conversation with your healthcare provider and, where appropriate, a nephrologist.
*Compounded semaglutide is not FDA-approved and has not been studied in dedicated kidney or cardiovascular outcomes trials. This content is for educational purposes only and is not a substitute for medical advice. Individual results vary. Care at Prescriva is delivered by independently licensed providers, not by Blue Oak Services LLC dba Prescriva, which is a management services organization. Prescriva providers conduct individual medical evaluations before any treatment is prescribed.*
---
References
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N Engl J Med.* 2024;391(2):109-121. PMID: 38785209
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med.* 2023;389(24):2221-2232. PMID: 37952131
- Ramadurgum P, Sharma K, Pinon A, Kattamuri L, Botros M. GLP-1 receptor agonists and cardiovascular and kidney outcomes by body mass index in type 2 diabetes. *Curr Cardiol Rep.* 2026;28(1):42. PMID: 41880122
Stay informed
Weekly research updates and health guides. No spam.
Ready to get started?
Check if you qualify for a personalized treatment plan.
Check Your Eligibility →Continue reading
Semaglutide Nausea: Why It Happens and How to Manage It
Does Semaglutide Cause Thyroid Cancer? What the Research Actually Shows
